COMMITTED TO PATIENT SAFETY...
XARELTO® establishing real-world outcomes
IMPORTANT SAFETY INFORMATION (cont’d)
Nursing Mothers: It is not known if rivaroxaban is
excreted in human milk.
Pediatric Use: Safety and effectiveness in pediatric
patients have not been established.
Females of Reproductive Potential: Females of
reproductive potential requiring anticoagulation
should discuss pregnancy planning with their physician.
ADVERSE REACTIONS IN CLINICAL STUDIES
The most common adverse reactions with
XARELTO® were bleeding complications.
Please see accompanying Brief Summary of full
Prescribing Information, including Boxed WARNINGS,
or visit www.XareltoHCP.com/PI.
052840-160508
USE IN SPECIFIC POPULATIONS (cont’d)
OVERDOSAGE
S:13 in
T:14 in
B:14.25 in
Discontinue XARELTO® and initiate appropriate
therapy if bleeding complications associated with
overdosage occur. A specific antidote for rivaroxaban
is not available. The use of activated charcoal to
reduce absorption in case of XARELTO® overdose
may be considered. Due to the high plasma protein
binding, rivaroxaban is not dialyzable.
References: 1. Data on file. Janssen Pharmaceuticals, Inc. Based on IMS Health, NPA Weekly, February 2016. 2. Beyer-Westendorf J, Förster K, Pannach S, et al. Rates,
management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-962. 3. Beyer-Westendorf J, Lützner J, Donath
L, et al. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery. Find